Savara price target raised to $16 from $7 at Piper Sandler
PremiumThe FlySavara price target raised to $16 from $7 at Piper Sandler
7M ago
A New Cause for Concern: CymaBay Therapeutics Inc Adds a New Corporate Activity and Growth Risk
Premium
Company Announcements
A New Cause for Concern: CymaBay Therapeutics Inc Adds a New Corporate Activity and Growth Risk
7M ago
CymaBay reports Q4 EPS (35c), consensus (31c)
Premium
The Fly
CymaBay reports Q4 EPS (35c), consensus (31c)
7M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
7M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
7M ago
CymaBay downgraded to Market Perform from Outperform at LifeSci Capital
Premium
The Fly
CymaBay downgraded to Market Perform from Outperform at LifeSci Capital
7M ago
CymaBay downgraded to Market Perform from Strong Buy at Raymond James
PremiumThe FlyCymaBay downgraded to Market Perform from Strong Buy at Raymond James
7M ago
CymaBay downgraded to Neutral from Buy at B. Riley
Premium
The Fly
CymaBay downgraded to Neutral from Buy at B. Riley
7M ago
CymaBay downgraded to Neutral from Overweight at Cantor Fitzgerald
Premium
The Fly
CymaBay downgraded to Neutral from Overweight at Cantor Fitzgerald
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100